Nuveen
ALLO icon

Nuveen’s Allogene Therapeutics ALLO Stock Holding History

Nuveen’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Sell
624,648
-1,690,444
-73% -$3.71M ﹤0.01% 2806
2026
Q1 		$5.65M Buy
2,315,092
+2,043,085
+751% +$4.1M ﹤0.01% 1829
2025
Q4 		$373K Hold
272,007
– – ﹤0.01% 2982
2025
Q3 		$337K Hold
272,007
– – ﹤0.01% 3027
2025
Q2 		$307K Buy
272,007
+56,641
+26% +$75.3K ﹤0.01% 3043
2025
Q1 		$13.3M Sell
215,366
-85,505
-28% -$161K ﹤0.01% 1377
2024
Q4 		$641K Buy
300,871
+46,632
+18% +$115K ﹤0.01% 2893
2024
Q3 		$712K Buy
254,239
+15,170
+6% +$40.4K ﹤0.01% 2891
2024
Q2 		$557K Sell
239,069
-63,186
-21% -$186K ﹤0.01% 2950
2024
Q1 		$1.35M Sell
302,255
-55,303
-15% -$231K ﹤0.01% 2575
2023
Q4 		$1.15M Sell
357,558
-2,643
-0.7% -$7.5K ﹤0.01% 2672
2023
Q3 		$1.14M Buy
360,201
+23,337
+7% +$102K ﹤0.01% 2524
2023
Q2 		$1.67M Buy
336,864
+63,186
+23% +$342K ﹤0.01% 2431
2023
Q1 		$1.35M Buy
273,678
+56,329
+26% +$361K ﹤0.01% 2493
2022
Q4 		$1.37M Sell
217,349
-129,820
-37% -$1.2M ﹤0.01% 2548
2022
Q3 		$3.75M Sell
347,169
-227,183
-40% -$3.09M ﹤0.01% 2060
2022
Q2 		$6.55M Sell
574,352
-105,469
-16% -$936K ﹤0.01% 1774
2022
Q1 		$6.45M Buy
679,821
+338,767
+99% +$3.53M ﹤0.01% 1921
2021
Q4 		$5.09M Sell
341,054
-104,476
-23% -$1.84M ﹤0.01% 2098
2021
Q3 		$11.4M Sell
445,530
-128,074
-22% -$3.04M ﹤0.01% 1686
2021
Q2 		$15M Buy
573,604
+345,555
+152% +$9.85M ﹤0.01% 1596
2021
Q1 		$8.05M Sell
228,049
-7,316
-3% -$247K ﹤0.01% 1915
2020
Q4 		$5.94M Sell
235,365
-118,130
-33% -$3.85M ﹤0.01% 1980
2020
Q3 		$13.3M Sell
353,495
-10,374
-3% -$391K 0.01% 1327
2020
Q2 		$15.6M Buy
363,869
+211,485
+139% +$7.65M 0.01% 1196
2020
Q1 		$2.96M Buy
152,384
+1,589
+1% +$37.8K ﹤0.01% 1991
2019
Q4 		$3.92M Sell
150,795
-422,232
-74% -$11.6M ﹤0.01% 2119
2019
Q3 		$15.6M Buy
573,027
+15,595
+3% +$444K 0.01% 1289
2019
Q2 		$15M Buy
+557,432
New +$15.5M 0.01% 1339

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen's ALLO Position: Q2 2026 in Review

Nuveen reduced its Allogene Therapeutics (ALLO) stake by 73% in Q2 2026, selling an estimated $3.71M and leaving 624,648 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Nuveen first reported a position in ALLO in Q2 2019 and has held it in 29 quarters since. The position peaked at $15.6M in Q3 2019. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Nuveen held 624,648 shares of Allogene Therapeutics worth $1.3M as of Q2 2026.
  • Nuveen sold 1,690,444 Allogene Therapeutics shares in Q2 2026, an estimated $3.71M.
  • Allogene Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2806 holding.
  • Nuveen first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Allogene Therapeutics position peaked at $15.6M in Q3 2019.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.